- Home
- CANF vs HIHO Comparison
CANF vs HIHO Comparison
Compare CANF & HIHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- HIHO
- Stock Information
- Founded
- CANF 1994
- HIHO 1990
- Country
- CANF Israel
- HIHO Hong Kong
- Employees
- CANF N/A
- HIHO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- HIHO Industrial Machinery/Components
- Sector
- CANF Health Care
- HIHO Industrials
- Exchange
- CANF Nasdaq
- HIHO Nasdaq
- Market Cap
- CANF 9.4M
- HIHO 8.5M
- IPO Year
- CANF N/A
- HIHO 1996
- Fundamental
- Price
- CANF $1.54
- HIHO $1.89
- Analyst Decision
- CANF Strong Buy
- HIHO
- Analyst Count
- CANF 2
- HIHO 0
- Target Price
- CANF $14.00
- HIHO N/A
- AVG Volume (30 Days)
- CANF 117.2K
- HIHO 12.2K
- Earning Date
- CANF 02-03-2025
- HIHO 01-21-2025
- Dividend Yield
- CANF N/A
- HIHO 6.35%
- EPS Growth
- CANF N/A
- HIHO N/A
- EPS
- CANF N/A
- HIHO N/A
- Revenue
- CANF $667,000.00
- HIHO $7,345,000.00
- Revenue This Year
- CANF $409.56
- HIHO N/A
- Revenue Next Year
- CANF N/A
- HIHO N/A
- P/E Ratio
- CANF N/A
- HIHO N/A
- Revenue Growth
- CANF N/A
- HIHO 11.36
- 52 Week Low
- CANF $1.29
- HIHO $1.70
- 52 Week High
- CANF $4.69
- HIHO $2.88
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- HIHO 42.15
- Support Level
- CANF $1.55
- HIHO $1.95
- Resistance Level
- CANF $1.64
- HIHO $1.97
- Average True Range (ATR)
- CANF 0.10
- HIHO 0.05
- MACD
- CANF 0.01
- HIHO -0.01
- Stochastic Oscillator
- CANF 11.76
- HIHO 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.